Last reviewed · How we verify
Methotrexate + Methylprednisolone
Methotrexate inhibits dihydrofolate reductase to suppress cell proliferation and immune activation, while methylprednisolone provides corticosteroid-mediated anti-inflammatory and immunosuppressive effects.
Methotrexate inhibits dihydrofolate reductase to suppress cell proliferation and immune activation, while methylprednisolone provides corticosteroid-mediated anti-inflammatory and immunosuppressive effects. Used for Rheumatoid arthritis, Systemic lupus erythematosus, Vasculitis.
At a glance
| Generic name | Methotrexate + Methylprednisolone |
|---|---|
| Sponsor | Université Catholique de Louvain |
| Drug class | Antimetabolite + Corticosteroid combination |
| Target | Dihydrofolate reductase (methotrexate); Glucocorticoid receptor (methylprednisolone) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Methotrexate is a folate antagonist that inhibits DNA synthesis and cell division, making it effective as both a chemotherapy agent and immunosuppressant. Methylprednisolone is a glucocorticoid that suppresses inflammatory cytokine production and immune cell activation. Together, this combination provides synergistic immunosuppression and anti-inflammatory activity, commonly used in autoimmune and inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Autoimmune inflammatory conditions
- Vasculitis
Common side effects
- Bone marrow suppression
- Infection
- Gastrointestinal toxicity
- Hepatotoxicity
- Immunosuppression-related complications
- Corticosteroid-related side effects (hyperglycemia, osteoporosis)
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) (PHASE3)
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (PHASE3)
- Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (PHASE2)
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PHASE3)
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methotrexate + Methylprednisolone CI brief — competitive landscape report
- Methotrexate + Methylprednisolone updates RSS · CI watch RSS
- Université Catholique de Louvain portfolio CI